Vivimed Labs admitted to insolvency resolution by NCLT

NCLT admitted insolvencyRegulatory & Legal View source PDF Explain this filing

VIVIMEDLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹7.75

prior close

₹7.81

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.6%-0.7% vs market

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.5

10m

+2.4

15m

+0.0

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs market

Reaction day

-1.3-0.6-0.7

Next day

-6.5+0.5-6.9

-11.1+1.8-12.9

-11.6+1.6-13.2

-13.2+0.1-13.3

-11.1+2.5-13.6

-9.0+2.4-11.4

15d

-17.0+1.9-18.9

-15.5+2.1-17.6

-23.9+12.5-36.3

-31.6+12.0-43.6

UpDownMarket · Nifty Microcap 250Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NCLT Bengaluru admitted Vivimed Labs to Corporate Insolvency Resolution Process (CIRP) on April 15, 2026, following a petition by Blue Cube Germany Assets GmbH, an operational creditor, for unpaid debt of ₹32.79 crore (including interest) from chemical supplies made in 2012-2014. A moratorium is in effect, the board of directors is suspended, and an Interim Resolution Professional has been appointed. Next hearing: June 24, 2026.

Likely market impact

Major negative: stock likely to hit lower circuit, equity may be diluted/written off in resolution, and lenders gain control of the company.